Head-to-head evidence
Iloperidone (PD psychosis use) vs Perseris
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Schizophrenia
Shared mechanism: Dopamine D2 and serotonin 5-HT2A receptors (antagonist) · full Schizophrenia pipeline
Iloperidone (PD psychosis use) · Fanapt
Marketed by Vanda Pharmaceuticals
NCT00254202 · Phase 3 · completed
The trial was randomized and quadruple-blind, included both placebo and active control groups, and enrolled 593 participants. Its primary clinical symptom endpoint was PANSS-T change, with mean changes of -12.0 for iloperidone versus -7.1 for placebo, but statistical significance of the comparison is not reported, so the result remains unclear.
Next expected readout: November 2027 · NCT06961968 (registry estimate)
Perseris
Marketed by Indivior Pharmaceuticals, Inc.
NCT02109562 · Phase 3 · completed
This was a randomized, double-blind, placebo-controlled trial with 354 participants and a clinical primary endpoint measuring change in PANSS total score. The primary endpoint was met for both RBP-7000 doses: PANSS scores improved significantly more than with placebo.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Iloperidone (PD psychosis use)'s landscape · Perseris's landscape